Please contact us for more information or to learn if you are eligible to participate.
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. The approach that we will take in this trial is to focus on finding agents with a big impact on reducing both mortality and time on ventilators for those critically ill as a result of COVID 19. Both of these endpoints are critical to managing the health crisis created by the global pandemic.
Principal Investigator | Praveen Vijhani, MD |
Co-PI | Luis Cantu Jr. |
Sponsor | National Center for Advancing Translation Sciences |
Type of Trial | Interventional |